share_log

Oppenheimer Reiterates Outperform on Cellectis, Maintains $11 Price Target

Benzinga ·  Aug 8, 2023 11:40

Oppenheimer analyst Hartaj Singh reiterates Cellectis (NASDAQ:CLLS) with a Outperform and maintains $11 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment